Evidence map›Paper›PMID 42015769›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026

No. 2 Kangxianling decoction protects against renal ischemia/reperfusion injury by hypoxia-inducible factor activation.

Y U Kena, Zhong Liping, Lin Xiaomeng, Chen Jian, H E Liqun, Cai Xudong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Y U KenaDepartment of Nephrology,Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University,Ningbo315000,China.
Zhong LipingDepartment of Nephrology,Hubei Provincial Hospital of Integrated Traditional Chinese and Western Medicine,Wuhan430000,China.
Lin XiaomengDepartment of Nephrology,Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University,Ningbo315000,China.
Chen JianDepartment of Traditional Medicine,Shanghai Integrated Traditional Chinese and Western Medicine Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai200082,China.
H E LiqunDepartment of Nephrology,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai200013,China.
Cai XudongDepartment of Nephrology,Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University,Ningbo315000,China.

Funding

National Natural Science Foundation of China: Research on The Pathogenesis of Renal Micro Syndrome Accumulation in Chronic Renal Failure through Mammalian Target of Rapamycin Signaling Pathway and the Anti-fibrotic Effect of Kangxianling Decoction on Gene Knockout Mice 81373615Zhejiang Natural Science Foundation of China: Mechanism Study of Wenyangxiaozheng Decoction Alleviating Cellular Senescence and Ameliorating Renal Fibrosis by Regulating the Phosphatidylinositol 3-kinase/Protein Kinase B LBY24H290002
6 · The paper itself

Abstract

objectiveTo investigate the effect of No. 2 Kangxianling decoction (，No. 2 KXLD) on renal tubular injury in renal ischemia/reperfusion injury (RIRI) rats and explore the mechanisms.

methodsMale Sprague-Dawley rats were divided into sham group, RIRI group, No. 2 KXLD group, and FG-4592 group. Rats were pretreated with No. 2 KXLD (30 g·kg

resultsNo. 2 KXLD significantly decreased the levels of Scr by 22.4% and BUN by 19.7% at 48 h after I/R and improved the renal pathological changes in RIRI rats. No. 2 KXLD attenuated the expression of kidney injury molecule-1, neutrophil-gelatinase-associated lipocalin, and tissue inhibitor of metalloproteinase-2 in RIRI rats and H/R-induced HK-2 cells (

conclusionsNo. 2 KXLD might have therapeutic potential on RIRI by inhibiting HIF-mediated inflammation and apoptosis, which provides a theoretical basis for the treatment of patients with renal tubulointerstitial injury.

Indexed as

Drugs, Chinese HerbalHypoxia-Inducible Factor 1KidneyKidney DiseasesProtective AgentsReperfusion InjuryAnimalsApoptosisHumansMaleRatsRats, Sprague-DawleyTumor Necrosis Factor-alphaDrugs, Chinese HerbalHypoxia-Inducible Factor 1Protective AgentsTumor Necrosis Factor-alphaFG-4592hypoxia-inducible factorNo. 2 Kangxianling decoctionrenal tubular injuryreperfusion injury

Identifiers

PMID42015769
PMCPMC13077114

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.